GW-TT2
Recent-onset Tinnitus; Hearing Loss in SSNHL & Ménière's disease
Phase 1Active
Key Facts
Indication
Recent-onset Tinnitus; Hearing Loss in SSNHL & Ménière's disease
Phase
Phase 1
Status
Active
Company
About Gateway Biotechnology
Gateway Biotechnology is a private, clinical-stage company pioneering novel treatments for hearing loss and tinnitus. Its lead program, GW-TT2, is an intranasal formulation of a repurposed drug targeting recent-onset tinnitus and is advancing under the FDA's 505(b)(2) regulatory pathway to reduce cost and risk. The company's scientific foundation is built on proprietary behavioral detection models and the expertise of its academic co-founders from Washington University in St. Louis and the University of Pittsburgh.
View full company profile